Drug Trial Radar · NCT01855750
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
838
Actual
Start
Sep 3, 2013
Primary completion
Feb 26, 2018
Study completion Apr 5, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Pharmacyclics LLC.
- First posted
- May 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.
Conditions
- Lymphoma
Interventions
IbrutinibDrug
560 mg capsules administered by mouth once daily (21-day cycles)
PlaceboDrug
4 matched capsules administered by mouth once daily (21-day cycles)
RituximabDrug
375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
CyclophosphamideDrug
750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
DoxorubicinDrug
50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
VincristineDrug
1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Prednisone (or equivalent)Drug
100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS) - Intent-to-Treat (ITT) PopulationTime frame: Up to 5.5 years
- Event-Free Survival (EFS) - Activated B-Cell (ABC) PopulationTime frame: Up to approximately 4.5 years
Locations
201 sites in 27 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Greenbrae, California
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Salinas, California
Site not named
Stanford, California
Site not named
Danbury, Connecticut
Site not named
Hartford, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Atlanta, Georgia
Site not named
Marietta, Georgia
Site not named
Peoria, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Goshen, Indiana
Site not named
Indianapolis, Indiana
Site not named
Topeka, Kansas
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Hackensack, New Jersey
Site not named
New Brunswick, New Jersey
Site not named
Fresh Meadows, New York
Site not named
Johnson City, New York
Site not named
Mineola, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
The Bronx, New York
Site not named
Charlotte, North Carolina
Site not named
Greenville, North Carolina
Site not named
Hickory, North Carolina
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
North Charleston, South Carolina
Site not named
Nashville, Tennessee
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.